Background: Although various case-control studies have been conducted to investigate the relationship between ADRB2 gene polymorphisms and asthma risk in different population groups, the results have been conflicting and inconclusive.
Introduction
Asthma, which is characterised by variable airway obstruction caused by bronchial hyperreactivity and airway inflammation, is one of the most common chronic respiratory diseases worldwide. It is a common and combinatorial disorder with genetic, lifestyle and environmental determinants. 1 It is prevalent in developed nations and is becoming an important health issue in many developing countries. Asthma currently affects almost 6.8 million children in the US and 1.1 million in the UK. It accounts for nearly 500,000 hospitalisations, 2 million emergency department visits, about 10,000 paediatric intensive care unit admissions, and 5,000 deaths in the United States each year. [2] [3] [4] The high prevalence of asthma in children has been reported in the UK, with an estimated prevalence of 1 in 9. 5 Visits to the doctor because of asthma have more than doubled in the last decade. 4 Despite some advances in treatment, it is a major cause of socioeconomic burden on the healthcare system and results in a poor quality of life for sufferers.
The aetiology of asthma is not yet clear. An increasing number of studies have focused on asthma genetics research. [6] [7] [8] Therefore, the identification of asthma susceptibility genes contributing to asthma pathogenesis is important. In a large number of asthma susceptibility genes, the beta-2 adrenergic receptor (ADRB2, also known as beta2-AR) gene has been extensively studied.
ADRB2 is located on chromosome 5q31-32, encodes 413 amino acids, and is an intronless gene. 9 ADRB2 is a non-intronic, relatively small (1.2-kb) gene that encodes a protein of 413 amino acids. There are more than 100 SNPs in the promoter region, five SNPs in the 5'UTR region and 18 SNPs in the coding region of the gene. The activation of beta2-AR can result in the expansion of the small airways, and thus beta2-AR agonists are used in first-line bronchodilator therapy in asthma. 10 It has also been reported that ADRB2 variants are associated with airway hypersensitivity, asthma severity, and the response to medications. 11, 12 In the ADRB2 gene, numerous polymorphisms have been identified. The most widely analysed singlenucleotide polymorphisms (SNPs) in the coding gene region include Arg16Gly (A46G, rs1042713), Gln27Glu (C79G, rs1042714), Thr164Ile (C491T, rs1800888) and Arg19Cys (T-47C, rs1042711). 13 The mutation of the two most important SNPs, Arg16Gly and Gln27Glu, which are located at nucleotide positions 46 and 79 of the coding region of the ADRB2 gene, respectively, can cause changes in the amino acid sequence. The altered amino acid sequence leads to down-regulation of B2-AR. B2-AR binds specifically to a class of ligands that can lead to the expansion of the small airways. Thr164Ile is also located in the coding region of theADRB2 gene, which can cause a change in amino acid from threonine (Thr) to isoleucine (Ile). Moreover, studies of the ADRB2 gene have not been confined to coding region polymorphisms alone, as increasingly more studies have begun to pay attention to promoter region polymorphisms. Arg19Cys is located in the 5' leader region that harbours an open reading frame (ORF) in the promoter region of the ADRB2 gene, which can impede the translation of ADRB2 mRNA, and regulate cellular expression of the receptor. 14 Therefore, we chose the above four important SNPs in the current study.
Although various case-control studies have been conducted to investigate the relationship between the ADRB2 gene polymorphisms and asthma risk in different populations, the results have been conflicting and inconclusive 15, 16 . To confirm the association between SNPs from the ADRB2 gene and asthma, we performed a case-control study for the association of all 4 SNPs from the ADRB2 gene with risk of asthma in Chinese children, and then conducted a meta-analysis to derive a relatively comprehensive picture of the relationship between the ADRB2 gene polymorphisms and asthma risk in children.
Methods

Study design
This was a hospital-based case-control study conducted in the Department of Paediatrics, The Affiliated Hospital of Qingdao University, between September 2010 and May 2014. The present study was approved by the ethics committee of Qingdao University, and all participants gave written, informed consent.
Subjects
We recruited 680 subjects (340 asthmatic and 340 controls) of the same ethnicity. In screening of asthma, asthma diagnosis was made according to GINA recommendations, based on clinical asthma symptoms and lung function test (bronchodilator responsiveness, exercise-induced hyperresponsiveness). The subjects were excluded because of pneumonia, tuberculosis, disseminated bronchiectasis, bronchiolitis, pneumothorax, pyothorax, immunocompromised status, malignancy and age above 15 years. The control group met the following criteria: (1) 1-15 years of age, no present symptoms or history of asthma or other respiratory disease, (2) no history of atopy and (3) no family history of asthma in mother, father or sibling. Severe asthma was defined as follows: symptoms requiring daily therapy with high-dose inhaled corticosteroids (> 800 budesonide or > 500 fluticasone), despite regular treatment with long-acting 2-agonists and/or leukotriene antagonist and/or theophylline (slow releasing), and 1 or more emergency care visit or oral steroid burst per year.
Genomic DNA extraction and genotyping of ADRB2 variants
We selected the Arg16Gly (rs1042713), Gln27Glu (rs1042714), Thr164Ile (rs1800888) and Arg19Cys (rs1042711) single nucleotide polymorphisms (SNPs) for association analysis. Genomic DNA was extracted from peripheral blood leukocytes using genomic DNA isolation kits (Promega, Madison, WI) according to the manufacturer's instructions. The primers, probes and reaction conditions are available upon request. SNPs were genotyped by the PCR-based invader assay (Third Wave Technologies) using an ABI 7900 (Applied Biosystems, Foster City, CA, WI). 
Meta-analysis
Firstly, studies were included if they were casecontrol or cohort studies that evaluated the association between the ADRB2 gene polymorphisms and risk of asthma and included data about the genotype distributions or allele frequency of the above 4 SNPs in the ADRB2 gene. Secondly, two of the authors independently extracted th following data from each full-text report using a standard data extraction form. The data extracted from the studies included the title, authors, year of publication, study design, number of cases or controls, ethnicity, genotyping method, genotype distribution, and allele frequency of the 4 SNPs in cases or controls.
Statistical analysis
Standard  analysis was used to examine differences in allelic frequencies and genotype distributions of the 4 SNPs between asthmatic patients and controls in case-control study. Hardy-Weinberg equilibrium was tested by a goodness-of-fit test were used to assess the effect of heterogeneity. Heterogeneity was considered statistically significant when Q-test (P <0.10) or I 2 >50%. If heterogeneity was indicated, data were combined according to the random-effects model; when the Q-test (P >0.10) or I 2 <50%, the fixedeffect model was used. Stratified analysis was performed by ethnicity. Publication bias was conducted both visually by using a funnel plot and statistically via Begg funnel plots and Egger's bias test, which measure the degree of funnel plot asymmetry.
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Results
Demographic details
A total of 680 subjects (340 cases and 340 controls) were successfully genotyped and subjected to statistical analysis. 
Association of ADRB2 gene variants with asthma compared with controls in the case-control study
The distributions of the alleles and genotypes for the 4 SNPs of the ADRB2 gene (including rs1042713, rs1042714, rs1800888, and rs1042711) were presented in Table 2 . Genotype frequencies of the GDM group and the control group conformed to Hardy-Weinberg equilibrium. In accordance with the genome-wide association study (GWAS), no significant association was found between the polymorphisms rs1042713, rs1042714, rs1800888, and rs1042711 and asthma in the current casecontrol study.
Meta-analysis
A total of 96 titles and abstracts were preliminarily reviewed, of which 13 of the published studies eventually satisfied the eligibility criteria. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] All of the included studies investigated the relationship between one of the 4 SNPs and asthma. We therefore performed a meta-analysis by combining previous studies and the present casecontrol study. Ultimately, 14 studies investigated the relationship between Arg16Gly (rs1042713) and asthma, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] 12 studies studied Gln27Glu (rs1042714), 20, 21, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] 2 studies focused on Thr164Ile (rs1800888), 21 and 2 studies on Arg19Cys (rs1042711). 24 Characteristics of the studies that were included in the meta-analysis are presented in Table 3 .
For Arg16Gly (rs1042713), there was no significant association in any of the genetic model comparisons in the Asia, South American, European and overall populations ( Figure 1 , Table 4 ). ForGln27Glu (rs1042714), no evidence of an association with asthma risk was found in the South American and European population in any of the genetic model comparisons. A significant association was found in the Asia population in the dominant model and homozygote model comparison, but not in the other genetic comparisons (Figure 2 , Table 4 ). For Thr164Ile (rs1042713), only two case-control studies in Asia were included. There was no evidence of any association with asthma risk in any of the genetic models in the Asia population (Table 4) . For Arg19Cys (rs1042711), only two case-control studies provided genotype distribution data. No significant association was found in the Asia, European and overall population in any of the genetic models (Table 4) .
Publication bias
The publication bias test was performed for the Arg16Gly and Gln27Glu polymorphism in all of the model comparisons. No significant publication bias was shown by Begg rank correlation method and Egger weighted regression method.
Discussion
In the present study, the relationship between all 4 related ADRB2 gene polymorphisms and the overall risk of asthma was examined in a casecontrol study. Furthermore, a meta-analysis was also conducted to evaluate the pooled results of the association between the ADRB2 gene polymorphisms and risk of asthma in children. The pathogenesis of asthma in adults and children may differ, but the exact mechanism remains unknown and needs further detailed research. Therefore, the present case-control study and meta-analysis was performed only in children. The purpose of the present study was to provide more information for asthma candidate gene research in children.
Four ADRB2 polymorphisms were included in the study. The results indicated that Arg16Gly, Gln27Glu, Thr164Ile, and Arg19Cys were not associated with the risk of asthma in the present population. The extensive studies on Arg16Gly and Gln27Glu polymorphisms were based on their localisation within (codon 16) or in the vicinity (codon 27) of 2 tripeptides (N-X-S/T) that form a consensus for N-glycosylation involved in receptor expression on the cell surface and in binding to G s proteins. 33, 34 The functionality of the Arg16Gly polymorphism was determined in vitro by Green et al., who demonstrated that the Gly allele was associated with more rapid receptor desensitisation in response to β 2 -agonists, in comparison to the Arg allele. In the case of the Gln27Glu polymorphism, the Glu variant underlies down-regulation to a lesser degree than Gln in cultures of human primary airway smooth muscle cells after chronic exposure to β 2 -agonists. That may suggest a protective role of this variant in regard to receptor desensitisation. In our case-control study and meta-analysis, we did not observe any association between the Arg16Gly and Gln27Glu polymorphisms and asthma in children.
The findings of the current study are consistent with previous studies. A meta-analysis showed a nonsignificant odds ratio for the Arg16Gly and Gln27Glu polymorphisms. Contopoulos-Ioannidis et al. conducted a meta-analysis and found that polymorphisms in the ADRB2 gene are not major risk factors for the development of asthma in the entire population.
11
Although the present study was confined to children, there was no significant association between the Arg16Gly polymorphism or the Gln27Glu polymorphism and the risk of asthma.
No significant association with the risk of asthma was found for the Thr164Ile and Arg19Cys polymorphisms. Therefore, the Thr164Ile and Arg19Cys polymorphisms may not be involved in the pathogenesis of asthma in children. However, as only two studies were included in the meta-analysis, there may have been insufficient statistical evidence to clarify the association between the Thr164Ile and Arg19Cys polymorphisms and the risk of asthma in children. Thus, further studies are still required.
In the meta-analysis, only the above four SNPs were investigated in the present study. Although several included studies reported an association between other SNPs and the risk of asthma, the limited number of studies which reported certain SNPs will lower the stability of the pooled results. Therefore, we chose the four widely investigated SNPs in the current meta-analysis. Further studies investigating the other SNPs may therefore be required in the future. Further meta-analyses combining the studies which state an association between the other SNPs and the risk of asthma could be conducted when there have been enough relevant studies.
Although Liang et al. 37 conducted a metaanalysis to assess the relationship between ADRB2 gene polymorphisms and asthma risk, all patients including adults and children were included in the study. The different age of patients in individual studies, as an obvious source of clinical heterogeneity, may introduce a risk of bias. Therefore, we performed the current meta-analysis by only including studies of children. However, the results of the present study were similar to those of previous studies.
The limitations of this meta-analysis include the following: (1) The efficacy of the statistics may be further improved by including more studies in the future, especially in the investigation of Thr164Ile and Arg19Cys polymorphisms. (2) In the current meta-analysis, we only included literature published in English and Chinese, thus neglecting studies 
Conclusion
The present study suggested that the ADRB2 gene polymorphisms Arg16Gly, Gln27Glu, Thr164Ile and Arg19Cys were not associated with susceptibility to asthma in the current population of children. The further meta-analysis provided additional evidence supporting the above result that these four polymorphisms may not be involved in the risk of asthma in the overall children population. Due to the limited data that are currently available, further well-designed studies with large sample sizes are still required.
